Seborrheic Dermatitis Overview:
Seborrheic dermatitis is a chronic, inflammatory skin disease that primarily affects areas with a high concentration of sebaceous glands, such as the scalp, face, chest, back, armpits, and groin. It is estimated that about 4% of the population is affected. Although the exact cause is unknown, seborrheic dermatitis is thought to be caused by an overgrowth of Malassezia, a harmless yeast that occurs naturally on the skin, or an overreaction of the immune system to this yeast. Diagnosis usually depends on the location and appearance of the rash or lesions, and a skin biopsy may be helpful, but is not usually necessary. Treatment focuses primarily on reducing the levels of yeast on the skin and often involves the long-term use of creams and shampoos.
For more insights into the seborrheic dermatitis pipeline, read the full report below:https://www.delveinsight.com/report-store/seborrhoeic-dermatitis-pipeline-insight?utm_source=reportutm_medium=promotionutm_campaign=hpr
Key Takeaways from the Seborrheic Dermatitis Pipeline Report:
DelveInsight's Seborrheic Dermatitis Pipeline Report reveals a thriving sector with over five active companies developing more than five therapies for the treatment of seborrheic dermatitis.
Like major companiesArcutis Biotherapeutics, Cutanea Life Sciences, DermBiont, Astion Pharma A/S, AmorepacificWe are actively evaluating new medications aimed at improving the treatment status of seborrheic dermatitis.
Notable pipeline therapies in various stages of development include:Topical roflumilast foam (ARQ-154), omiganan (CLS002), DBI-002, PAC-14028, among others.
Recent advances in the seborrheic dermatitis pipeline:
Recent studies have found that seborrheic dermatitis has a distinct immune profile that is distinct from conditions such as atopic dermatitis and plaque psoriasis. Furthermore, changes in specific gene expression are associated with disruption of the skin barrier.
- DermbiontCompleted enrollment in Phase 2b study ofSM-020 Gel 1.0%Intended for seborrheic keratosis, with topline data expected in Q3 2024. Positive results could initiate further discussions with the FDA regarding Phase 3 trial design.
- FDA approvedRoflumilast Foam 0.3% (Zoryve)For the treatment of seborrheic dermatitis in ages 9 and older. This steroid-free, once-daily form offers patients a new treatment option.
Seborrheic Dermatitis Pipeline Analysis:
This report provides detailed information on:
- Key companies involved in developing treatments for seborrheic dermatitis.
- A detailed assessment of different therapeutic candidates categorised by development stage (early, mid and late).
- Analysis of active and inactive (dormant or discontinued) projects of key companies.
- Insights into emerging medicines categorized by development stage, route of administration, target receptor, monotherapy or combination therapy, mechanism of action and molecule type.
- A detailed breakdown of collaborations (business-to-business and business-to-academic collaborations), licensing agreements, and funding strategies aimed at developing the Seborrheic Dermatitis market.
For a sample report, download your free Seborrheic Dermatitis Pipeline Insights page here.https://www.delveinsight.com/sample-request/seborrhoeic-dermatitis-pipeline-insight?utm_source=reportutm_medium=promotionutm_campaign=hpr
New drugs for seborrheic dermatitis:
- Topical Roflumilast Foam (ARQ-154):Arctis Biotherapeutics
- Omiganan (CLS002):Skin Life Sciences
- DBI-002:Dermbiont
- PAC-14028:Amorepacific
Seborrheic dermatitis companies:
Including some major companiesArctis Biotherapeutics, which is working on the treatment of seborrheic dermatitis. Some of these companies have drug candidates in the mid- to late-stage (especially Phase II) stages.
DelveInsight's report covers over five products across various stages of clinical development, including:
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early Stage Products (Phase I)
- Preclinical and discovery stage candidates
- Discontinued and inactive candidates
The Seborrheic Dermatitis Pipeline report provides a therapeutic assessment of pipeline drugs segmented as follows:
- Route of Administration (ROA):Intravenous, subcutaneous, oral, intramuscular
- Molecule type:Monoclonal antibodies, small molecules, peptides
For detailed insights on emerging treatments and key players in the Seborrheic Dermatitis market, download the full report here:https://www.delveinsight.com/report-store/seborrhoeic-dermatitis-pipeline-insight?utm_source=reportutm_medium=promotionutm_campaign=hpr
Seborrheic Dermatitis Treatment Rating:
- Seborrheic Dermatitis by Product Type
- Stages of seborrheic dermatitis
- Seborrheic dermatitis by route of administration
- Molecular types of seborrheic dermatitis
For a detailed assessment of the Seborrheic Dermatitis Treatment market, download the sample report.https://www.delveinsight.com/sample-request/seborrhoeic-dermatitis-pipeline-insight?utm_source=reportutm_medium=promotionutm_campaign=hpr
Contact Information:
Himanshu
hmason@delveinsight.com
info@delveinsight.com
+14699457679
About DelveInsight
DelveInsight is a leading business consultancy and market research firm focused on life sciences, supporting pharmaceutical companies by providing comprehensive end-to-end solutions to improve their business performance.
